Naitou K, Mamerto T P, Pustovit R V, Callaghan B, Rivera L R, Chan A J, Ringuet M T, Pietra C, Furness J B
Department of Anatomy & Neuroscience, University of Melbourne, Parkville, VIC, Australia.
Department of Basic Veterinary Science, Laboratory of Physiology, The United Graduate School of Veterinary Sciences, Gifu University, Gifu, Japan.
Neurogastroenterol Motil. 2015 Dec;27(12):1764-71. doi: 10.1111/nmo.12688. Epub 2015 Sep 28.
It has been recently demonstrated that the ghrelin receptor agonist, HM01, caused defecation in rats that were treated to provide a model for the constipation of Parkinson's disease. HM01 significantly increased fecal output and increased Fos activity in neurons of the hypothalamus and hindbrain, but not in the spinal defecation center. Other ghrelin agonists act on the defecation center.
Receptor pharmacology was examined in ghrelin receptor (GHSR1a) transfected cells. Anesthetized rats were used to investigate sites and mechanisms of action.
HM01 activated rat GHSR1a at nanomolar concentrations and was antagonized by the GHSR1a antagonist, YIL781. HM01, intravenous, was potent to activate propulsive colorectal contractions. This was prevented by pelvic nerve section and by intravenous YIL781, but not by spinal cord section rostral to the defecation centers. Direct intrathecal application of HM01 to the defecation center at spinal level L6-S1 initiated propulsive contractions of the colorectum.
CONCLUSIONS & INFERENCES: HM01 stimulates GHSR1a receptors on neurons in the lumbosacral defecation centers to cause propulsive contractions and emptying of the colorectum. It has greater potency when given systemically, compared with other GHSR1a agonists.
最近有研究表明,胃饥饿素受体激动剂HM01可使接受治疗以建立帕金森病便秘模型的大鼠排便。HM01显著增加粪便排出量,并增加下丘脑和后脑神经元中的Fos活性,但对脊髓排便中枢无此作用。其他胃饥饿素激动剂作用于排便中枢。
在转染胃饥饿素受体(GHSR1a)的细胞中检测受体药理学。使用麻醉大鼠研究作用部位和机制。
HM01在纳摩尔浓度下激活大鼠GHSR1a,并被GHSR1a拮抗剂YIL781拮抗。静脉注射HM01可有效激活结肠推进性收缩。盆腔神经切断和静脉注射YIL781可阻止这种收缩,但在排便中枢头侧的脊髓切断则不能。将HM01直接鞘内注射到脊髓L6-S1水平的排便中枢可引发结肠推进性收缩。
HM01刺激腰骶部排便中枢神经元上的GHSR1a受体,引起结肠推进性收缩和排空。与其他GHSR1a激动剂相比,全身给药时它的效力更强。